Avricore Health Supports the Globe and Mail's Health Innovation Event

Avricore Health Supports the Globe and Mail's Health Innovation Event

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") was honoured to join the Globe and Mail's recent Health Care Innovation event, featuring leaders from various corners of the sector, including Company CEO, Hector Bremner.

"With about 40% of patients in Canada saying it's difficult to access a diagnostics test and nine million expressing difficulty in getting access to care, it's clear that the time is now to support more services in community pharmacy," says Avricore Health Inc. CEO, Hector Bremner. "HealthTab is already playing a significant role in supporting better services in pharmacy and we're going to continue to advocate for patients, and providers, so better outcomes for all are achieved."

The Globe and Mail's event featured health sector leaders, academics, governmental agency representatives, physicians, and patient advocates. For a full list of participants and to watch the webcast in its entirety, it can be viewed at the Globe and Mail's site at the following link: https://www.theglobeandmail.com/events/article-new-approaches-to-health-care-delivery/ .

Also, for reference to the above-mentioned observations on Canadian patient experience and sentiment around the current healthcare challenges, please view the recent Angus Reid Institutes series of polling data here: https://angusreid.org/canada-health-care-issues/ .

HealthTab™ Market Fast Facts

  • Point of Care Testing Market to reach $93.21 Billion USD in 2030 ( Source ).
  • Nearly 13.6 Million Canadians expected to be diabetic or prediabetic by 2030, with many undiagnosed ( Source ).
  • Over 1 in 3 Americans, approximately 88 million people, have pre-diabetes ( Source ).
  • Close to 160,000 Canadians 20 years and older are diagnosed with heart disease each year, often it's only after a heart attack they are diagnosed ( Source ).
  • There are more than 10,000 pharmacies in Canada, 88,000 pharmacies in the US, nearly 12,000 in the UK.

About HealthTab™

HealthTab™ is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19.

The HealthTab™ network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API.

About Avricore Health Inc.

Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab™, a wholly owned subsidiary, the company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.

Contact :

Avricore Health Inc.
Hector Bremner, CEO 604-773-8943
info@avricorehealth.com
www.avricorehealth.com

Cautionary Note Regarding Forward-Looking Statements
Information in this press release that involves Avricore Health's expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

AVCR:CA
The Conversation (0)
Avricore Health Corporate Update - Company Demonstrates Strong Growth

Avricore Health Corporate Update - Company Demonstrates Strong Growth

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") reports on its third quarter results which demonstrate significant growth in pharmacy locations offering HealthTab driving strong revenue growth and operational cashflow positivity. With demand for clinical services growing in pharmacies thanks to the ever-expanding scope and demonstrated success they are having with it; the Company expects to finish the year well ahead of the year previous and have great momentum for 2024.

"Patients and pharmacists are discovering and accessing new information that's having a powerful impact on their care and support thanks to HealthTab," said Hector Bremner, CEO of Avricore Health Inc. "Our ambition of helping more people live better is becoming reality each day and we are poised to make big breakthroughs in bringing this service to more patients around the world."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
HealthTab Supports Patient Testing in the First Rexall® Pharmacy Walk-In Clinic

HealthTab Supports Patient Testing in the First Rexall® Pharmacy Walk-In Clinic

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is expanding its innovative point-of-care chronic and infectious disease screening and health-data management platform, HealthTab™, further into the Canadian pharmacy ecosystem with one of Canada's largest pharmacy retailers, Rexall Pharmacy Group ULC ("Rexall").

"With Pharmacies' expanded scope and rising patient demand, the need for the clinical pharmacy practice is greater than ever," said Hector Bremner, CEO of Avricore Health. "We're excited to work with Rexall pharmacy teams to support positive patient outcomes through real-time insights into their health."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avricore Health Corporate Update - Mid-Year Review Demonstrates Company on Right Track

Avricore Health Corporate Update - Mid-Year Review Demonstrates Company on Right Track

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") continues to achieve significant growth, new partnerships and developing new markets while surpassing margin targets. Now, as the Company looks back at the first half of the year, it continues with confidence on its strategy to bring HealthTab™, its turnkey solution for point of care testing and data management, to more pharmacies across Canada and the world.

"We've had an incredible year so far and we're very excited about what's still to come," said Hector Bremner, CEO of Avricore Health Inc. "Make no mistake, with new partners in Canada and expansion into the UK, we have nothing but blue sky in front of us."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
HealthTab Signs Reseller Agreement With Abbott to Support UK Expansion

HealthTab Signs Reseller Agreement With Abbott to Support UK Expansion

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is pleased to announce the signing of a reseller agreement between HealthTab™ Inc. and Abbott Rapid Dx UK & Ireland.

This agreement provides a foundation for HealthTab to purchase and distribute the Afinion™ 2 and associated tests for diabetes and heart disease screening in community pharmacies in the UK.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avricore's HealthTab Selected for Feasibility Study for Testing in Community Pharmacies in United Kingdom

Avricore's HealthTab Selected for Feasibility Study for Testing in Community Pharmacies in United Kingdom

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is pleased that HealthTab, the Company's leading pharmacy-based platform for testing and health data management, has been selected by a collaborative involving the internationally renowned Barts Heart Centre and HEART UK to assess the feasibility of community pharmacists in the UK's ability to complement opportunistic blood pressure checks with cholesterol testing to assess overall cardiovascular risk and build on the clinical services offered.

"In the wake of the pandemic, it's clear that the community pharmacy needs to play a bigger role in delivering more access to healthcare services, especially chronic disease screening and management," said Hector Bremner, CEO of Avricore Health. "We are honoured to have been selected for this important project and look forward to working with pharmacist as they support patients with this vital service."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Nextech3D.ai Receives Notice From USPTO To Be Granted Pivotal AI Patent for Generating 3D Models from 2D images

Nextech3D.ai Receives Notice From USPTO To Be Granted Pivotal AI Patent for Generating 3D Models from 2D images

Nextech3D.ai (OTCQX:NEXCF)(CSE:NTAR)(FSE:EP2), a Generative AI-Powered 3D model supplier for Amazon, P&G, Kohls and other major e-commerce retailers is excited to announce that U.S. Patent and Trademark Office (USPTO) has informed of their decision to issue a patent for its technology to generate three-dimensional (3D) models from two-dimensional (2D) images. This is another patent which the Company believes is pivotal to Nextech3D.ai's artificial intelligence technology as it builds a moat around its 3D model making for ecommerce business with industry expertise and intellectual property; which includes its GPT AI powered 3D model generation. This patent approval reinforces and validates Nextech3D.ai's commitment to increasing shareholder value by investing in 3D-AI GPT patents and solutions while simultaneously generating millions in annual 3D modeling revenue

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
E-Power Resources Inc. Announces Approval of Deal with Volt Carbon Technologies

E-Power Resources Inc. Announces Approval of Deal with Volt Carbon Technologies

E-Power Resources Inc (CSE: EPR) ("E-Power" or the "Company") is pleased to announce it has issued the first tranche of 1,600,000 shares to Volt Carbon Technologies Inc ("Volt Carbon") as part of the option agreement announced on February 5, 2024.

The Company issued 1,600,000 shares to Volt Carbon on March 21, 2024. The shares are subject to a 4-month hold period. The Company will issue Volt Carbon another 2,500,000 shares when $340,000 is spent on exploration of the Tetepisca Property and a further 2,500,000 shares when the second $340,000 is spent on exploration of the Tetepisca Property. Volt Carbon has agreed to spend the full $680,000 during the 2024 calendar year. Spending the entire $680,000 on exploration of the Tetepisca Property, before December 31, 2024, will give Volt Carbon the right to acquire a 5% interest in the Tetepisca Property, on or before December 31, 2025, for a $1,500,000 cash payment.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
ARway.ai Announces Major 300,000 SQ FT or 30,000 M. Retail Store Pilot of its AR Navigation Platform

ARway.ai Announces Major 300,000 SQ FT or 30,000 M. Retail Store Pilot of its AR Navigation Platform

ARway.ai ("ARway" or the "Company") (CSE:ARWY)(OTCQB:ARWYF)(FSE:E65) is an AI powered Augmented Reality Experience platform with a disruptive no-code, no beacon spatial computing solution enabled by visual marker tracking with centimeter precision is pleased to announce its new partnership with Megatek Albania's leading home improvement and do-it-yourself (DIY) retailer. This groundbreaking collaboration is set to bring an unprecedented retail experience to the Albanian market, beginning with a pilot program at Megatek's expansive flagship store that spans more than 323,000 square feet

The successful implementation of ARway's technology in Megatek's flagship store will pave the way for future deployments across more locations and similar stores, signaling a significant growth and revenue opportunity for both companies.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
NEO Battery Materials Announces Change of Auditor to MNP LLP

NEO Battery Materials Announces Change of Auditor to MNP LLP

NEO Battery Materials Ltd. (" NEO " or the " C o mpan y ") ( T S X V : NBM ) ( OTC: NBMFF ), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased to announce that it has changed its auditors from DeVisser Gray LLP (" Former Auditor ") to MNP LLP (" Successor Auditor "), effective March 19, 2024.

NEO Battery's board of directors accepted the resignation of DeVisser Gray LLP and appointed MNP LLP as the new auditor of the Company, effective March 19, 2024, until the Company's next annual general meeting of shareholders.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

NANALYSIS ANNOUNCES CLOSING OF PREVIOUSLY ANNOUNCED BEST EFFORTS PROSPECTUS EXEMPT OFFERING PURSUANT TO THE LISTED ISSUER EXEMPTION AND CONCURRENT PRIVATE PLACEMENT

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES ./

Nanalysis Scientific Corp. (TSXV: NSCI) (the " Company " or " Nanalysis ") is pleased to announce that it has closed its prospectus exempt offering of units (the " Offering ") and concurrent brokered "best efforts" prospectus exempt offering of units (the " Concurrent Offering" ), as announced on March 6, 2024 . A total of 11,111,110 units (the " Units ") were issued at a price of $0.45 per Unit for gross proceeds of $4,999,999.50 . A total of 8,888,888 Units were issued pursuant to the Offering and 2,222,222 Units were issued pursuant to the Concurrent Offering.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
ARway.ai Announces EWROS as New Partner in Turkey for its Augmented Reality Navigation Experience Platform

ARway.ai Announces EWROS as New Partner in Turkey for its Augmented Reality Navigation Experience Platform

ARway.ai ("ARway" or the "Company") (CSE:ARWY)(OTCQB:ARWYF)(FSE:E65) is an AI powered Augmented Reality Experience platform with a disruptive no-code, no beacon spatial computing solution enabled by visual marker tracking with centimeter precision is pleased to announce a paid partner deal with EWROS, a leading developer of automation systems software based out of Turkey. This new partner is another step in ARway.ai's expansion, aligning with EWROS's recognized position in the region as a premier automation solutions provider

EWROS becomes an integral part of the ARway ecosystem, licensing ARway's innovative platform for large-scale projects within the region. This partnership allows EWROS to leverage ARway's cutting-edge AR technology in conjunction with their existing IoT deployments, thereby offering a comprehensive tech stack to their clientele.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×